Vaccine against pneumococcal pneumonia in adults

New England Journal of Medicine

Volumn 373, Issue 1, 2015, Pages 91-93

  Swartz, Andrew W ^a  

^a Yukon Kuskokwim Health   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PNEUMOCOCCUS VACCINE;

ADULT; AGE DISTRIBUTION; COMMUNITY ACQUIRED PNEUMONIA; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; HOSPITALIZATION; HUMAN; INFECTION RISK; LETTER; MORTALITY; NUMBER NEEDED TO TREAT; OUTCOME ASSESSMENT; PARAMETERS; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SEROTYPE; STREPTOCOCCUS PNEUMONIA; VACCINATION; FEMALE; MALE; PNEUMONIA, PNEUMOCOCCAL;

FEMALE; HUMANS; MALE; PNEUMOCOCCAL VACCINES; PNEUMONIA, PNEUMOCOCCAL;

EID: 84936745363     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1505366     Document Type: Letter

References (2)

1. Bonten MJM, Huijts SM, Bolkenbaas M, et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med 2015;372:1114-25.
2. Hak E, Grobbee DE, Sanders EAM, et al. Rationale and design of CAPITA: A RCT of 13-valent conjugated pneumococcal vaccine efficacy among older adults. Neth J Med 2008;66:378-83.